Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.34 |
| ▸ | TDP2 | O95551 | 7/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22379774 | 1.00 | GABRA1 (0.34) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22379797 | 1.00 | GABRA1 (0.34) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22379779 | 1.00 | GABRA1 (0.34) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22377841 | 0.97 | TDP2 (0.34) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22378247 | 0.97 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22377580 | 0.97 | TDP2 (0.34) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22379772 | 0.97 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22377834 | 0.97 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22379804 | 0.97 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22377835 | 0.97 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-10-24 | — | — | US | disclosed |
| US-20200274074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200274074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CYP1A1, CRY2 | GABRA1 1043/4885GABRG2 1996/4885GABRB3 2612/4885 |
| US-11800797-B2 | Heterocyclic compound and organic light-emitting device including the same | CRY1, CYP1A1, CRY2 | GABRA1 1043/4885GABRG2 1996/4885GABRB3 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.